nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—muscle cancer	0.528	1	CbGaD
Pomalidomide—PTGS2—Etoposide—muscle cancer	0.0737	0.227	CbGbCtD
Pomalidomide—CYP1A2—Dacarbazine—muscle cancer	0.0568	0.175	CbGbCtD
Pomalidomide—ABCB1—Dactinomycin—muscle cancer	0.0431	0.132	CbGbCtD
Pomalidomide—CYP1A2—Etoposide—muscle cancer	0.0278	0.0855	CbGbCtD
Pomalidomide—ABCB1—Vincristine—muscle cancer	0.0265	0.0816	CbGbCtD
Pomalidomide—ABCB1—Etoposide—muscle cancer	0.0243	0.0747	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—muscle cancer	0.0166	0.051	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—muscle cancer	0.0161	0.0494	CbGbCtD
Pomalidomide—CYP3A4—Vincristine—muscle cancer	0.0159	0.0489	CbGbCtD
Pomalidomide—CYP3A4—Etoposide—muscle cancer	0.0146	0.0448	CbGbCtD
Pomalidomide—CYP3A4—Doxorubicin—muscle cancer	0.00994	0.0305	CbGbCtD
Pomalidomide—Lenalidomide—PTGS2—muscle cancer	0.00273	0.625	CrCbGaD
Pomalidomide—TNF—vagina—muscle cancer	0.00244	0.11	CbGeAlD
Pomalidomide—CRBN—embryo—muscle cancer	0.00213	0.0958	CbGeAlD
Pomalidomide—PTGS2—hindlimb—muscle cancer	0.00203	0.0916	CbGeAlD
Pomalidomide—PTGS2—appendage—muscle cancer	0.00174	0.0785	CbGeAlD
Pomalidomide—Thalidomide—PTGS2—muscle cancer	0.00164	0.375	CrCbGaD
Pomalidomide—CRBN—renal system—muscle cancer	0.00161	0.0725	CbGeAlD
Pomalidomide—CRBN—cardiac atrium—muscle cancer	0.00144	0.0649	CbGeAlD
Pomalidomide—CRBN—tendon—muscle cancer	0.00126	0.0566	CbGeAlD
Pomalidomide—CRBN—bone marrow—muscle cancer	0.00122	0.0548	CbGeAlD
Pomalidomide—CRBN—vagina—muscle cancer	0.00117	0.0525	CbGeAlD
Pomalidomide—CRBN—head—muscle cancer	0.00108	0.0485	CbGeAlD
Pomalidomide—CRBN—testis—muscle cancer	0.00104	0.0469	CbGeAlD
Pomalidomide—Deep vein thrombosis—Methotrexate—muscle cancer	0.000775	0.00647	CcSEcCtD
Pomalidomide—Neuropathy—Etoposide—muscle cancer	0.000739	0.00617	CcSEcCtD
Pomalidomide—Embolism—Methotrexate—muscle cancer	0.000735	0.00613	CcSEcCtD
Pomalidomide—Hyponatraemia—Vincristine—muscle cancer	0.000708	0.00591	CcSEcCtD
Pomalidomide—Pain in extremity—Vincristine—muscle cancer	0.000705	0.00589	CcSEcCtD
Pomalidomide—Sepsis—Etoposide—muscle cancer	0.000683	0.0057	CcSEcCtD
Pomalidomide—Febrile neutropenia—Doxorubicin—muscle cancer	0.000679	0.00567	CcSEcCtD
Pomalidomide—Pelvic pain—Doxorubicin—muscle cancer	0.000671	0.0056	CcSEcCtD
Pomalidomide—Urinary retention—Vincristine—muscle cancer	0.000671	0.0056	CcSEcCtD
Pomalidomide—Interstitial lung disease—Methotrexate—muscle cancer	0.000666	0.00556	CcSEcCtD
Pomalidomide—Dehydration—Vincristine—muscle cancer	0.000656	0.00548	CcSEcCtD
Pomalidomide—Pancytopenia—Dactinomycin—muscle cancer	0.000648	0.00541	CcSEcCtD
Pomalidomide—Neutropenia—Dactinomycin—muscle cancer	0.000638	0.00533	CcSEcCtD
Pomalidomide—Embolism—Doxorubicin—muscle cancer	0.000636	0.00531	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Etoposide—muscle cancer	0.00063	0.00526	CcSEcCtD
Pomalidomide—Muscular weakness—Vincristine—muscle cancer	0.000622	0.0052	CcSEcCtD
Pomalidomide—Pneumonia—Dactinomycin—muscle cancer	0.000612	0.00511	CcSEcCtD
Pomalidomide—Hypercalcaemia—Doxorubicin—muscle cancer	0.000588	0.00491	CcSEcCtD
Pomalidomide—Pancytopenia—Vincristine—muscle cancer	0.000579	0.00484	CcSEcCtD
Pomalidomide—PTGS2—embryo—muscle cancer	0.000579	0.0261	CbGeAlD
Pomalidomide—Neutropenia—Vincristine—muscle cancer	0.00057	0.00476	CcSEcCtD
Pomalidomide—Weight decreased—Vincristine—muscle cancer	0.000552	0.00461	CcSEcCtD
Pomalidomide—Pneumonia—Vincristine—muscle cancer	0.000547	0.00457	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Vincristine—muscle cancer	0.000533	0.00445	CcSEcCtD
Pomalidomide—CYP1A2—renal system—muscle cancer	0.000529	0.0238	CbGeAlD
Pomalidomide—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.000519	0.00433	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Etoposide—muscle cancer	0.000504	0.00421	CcSEcCtD
Pomalidomide—Chills—Dactinomycin—muscle cancer	0.00049	0.00409	CcSEcCtD
Pomalidomide—Urinary tract disorder—Vincristine—muscle cancer	0.000482	0.00402	CcSEcCtD
Pomalidomide—Connective tissue disorder—Vincristine—muscle cancer	0.00048	0.004	CcSEcCtD
Pomalidomide—Urethral disorder—Vincristine—muscle cancer	0.000478	0.00399	CcSEcCtD
Pomalidomide—Pulmonary embolism—Methotrexate—muscle cancer	0.000472	0.00394	CcSEcCtD
Pomalidomide—Pancytopenia—Etoposide—muscle cancer	0.000469	0.00392	CcSEcCtD
Pomalidomide—Neutropenia—Etoposide—muscle cancer	0.000462	0.00386	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Methotrexate—muscle cancer	0.000455	0.0038	CcSEcCtD
Pomalidomide—PTGS2—smooth muscle tissue—muscle cancer	0.000455	0.0205	CbGeAlD
Pomalidomide—Cardiac disorder—Vincristine—muscle cancer	0.000453	0.00378	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.000449	0.00375	CcSEcCtD
Pomalidomide—Hypocalcaemia—Doxorubicin—muscle cancer	0.000446	0.00372	CcSEcCtD
Pomalidomide—Pneumonia—Etoposide—muscle cancer	0.000443	0.0037	CcSEcCtD
Pomalidomide—Angiopathy—Vincristine—muscle cancer	0.000443	0.0037	CcSEcCtD
Pomalidomide—Infestation NOS—Etoposide—muscle cancer	0.00044	0.00368	CcSEcCtD
Pomalidomide—Infestation—Etoposide—muscle cancer	0.00044	0.00368	CcSEcCtD
Pomalidomide—Mediastinal disorder—Vincristine—muscle cancer	0.00044	0.00367	CcSEcCtD
Pomalidomide—Anaemia—Dactinomycin—muscle cancer	0.000439	0.00367	CcSEcCtD
Pomalidomide—PTGS2—renal system—muscle cancer	0.000438	0.0197	CbGeAlD
Pomalidomide—Renal failure—Etoposide—muscle cancer	0.000433	0.00362	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Etoposide—muscle cancer	0.000432	0.0036	CcSEcCtD
Pomalidomide—Mental disorder—Vincristine—muscle cancer	0.000428	0.00357	CcSEcCtD
Pomalidomide—Bone pain—Doxorubicin—muscle cancer	0.000426	0.00356	CcSEcCtD
Pomalidomide—Leukopenia—Dactinomycin—muscle cancer	0.000426	0.00355	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Etoposide—muscle cancer	0.000416	0.00348	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Doxorubicin—muscle cancer	0.000413	0.00345	CcSEcCtD
Pomalidomide—Back pain—Vincristine—muscle cancer	0.000411	0.00343	CcSEcCtD
Pomalidomide—Sepsis—Methotrexate—muscle cancer	0.000409	0.00342	CcSEcCtD
Pomalidomide—Pulmonary embolism—Doxorubicin—muscle cancer	0.000408	0.00341	CcSEcCtD
Pomalidomide—Hyperkalaemia—Doxorubicin—muscle cancer	0.000401	0.00335	CcSEcCtD
Pomalidomide—Anaemia—Vincristine—muscle cancer	0.000393	0.00328	CcSEcCtD
Pomalidomide—Urinary tract disorder—Etoposide—muscle cancer	0.00039	0.00326	CcSEcCtD
Pomalidomide—Urethral disorder—Etoposide—muscle cancer	0.000388	0.00324	CcSEcCtD
Pomalidomide—Infection—Dactinomycin—muscle cancer	0.000386	0.00322	CcSEcCtD
Pomalidomide—Neuropathy—Doxorubicin—muscle cancer	0.000383	0.0032	CcSEcCtD
Pomalidomide—CYP3A4—renal system—muscle cancer	0.000383	0.0172	CbGeAlD
Pomalidomide—Vertigo—Vincristine—muscle cancer	0.000382	0.00319	CcSEcCtD
Pomalidomide—Leukopenia—Vincristine—muscle cancer	0.00038	0.00318	CcSEcCtD
Pomalidomide—Thrombocytopenia—Dactinomycin—muscle cancer	0.00038	0.00317	CcSEcCtD
Pomalidomide—Cardiac disorder—Etoposide—muscle cancer	0.000367	0.00306	CcSEcCtD
Pomalidomide—Angiopathy—Etoposide—muscle cancer	0.000359	0.003	CcSEcCtD
Pomalidomide—ABCB1—embryo—muscle cancer	0.000358	0.0161	CbGeAlD
Pomalidomide—Mediastinal disorder—Etoposide—muscle cancer	0.000356	0.00298	CcSEcCtD
Pomalidomide—Chills—Etoposide—muscle cancer	0.000355	0.00296	CcSEcCtD
Pomalidomide—Sepsis—Doxorubicin—muscle cancer	0.000354	0.00296	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000354	0.00295	CcSEcCtD
Pomalidomide—Infection—Vincristine—muscle cancer	0.000344	0.00288	CcSEcCtD
Pomalidomide—PTGS2—tendon—muscle cancer	0.000342	0.0154	CbGeAlD
Pomalidomide—Nervous system disorder—Vincristine—muscle cancer	0.00034	0.00284	CcSEcCtD
Pomalidomide—Thrombocytopenia—Vincristine—muscle cancer	0.000339	0.00283	CcSEcCtD
Pomalidomide—Decreased appetite—Dactinomycin—muscle cancer	0.000337	0.00282	CcSEcCtD
Pomalidomide—Hyperhidrosis—Vincristine—muscle cancer	0.000335	0.0028	CcSEcCtD
Pomalidomide—Fatigue—Dactinomycin—muscle cancer	0.000335	0.00279	CcSEcCtD
Pomalidomide—Back pain—Etoposide—muscle cancer	0.000333	0.00278	CcSEcCtD
Pomalidomide—Pain—Dactinomycin—muscle cancer	0.000332	0.00277	CcSEcCtD
Pomalidomide—PTGS2—bone marrow—muscle cancer	0.000331	0.0149	CbGeAlD
Pomalidomide—Muscle spasms—Etoposide—muscle cancer	0.000331	0.00276	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Doxorubicin—muscle cancer	0.000327	0.00273	CcSEcCtD
Pomalidomide—Feeling abnormal—Dactinomycin—muscle cancer	0.00032	0.00267	CcSEcCtD
Pomalidomide—Anaemia—Etoposide—muscle cancer	0.000318	0.00266	CcSEcCtD
Pomalidomide—PTGS2—vagina—muscle cancer	0.000317	0.0143	CbGeAlD
Pomalidomide—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000316	0.00264	CcSEcCtD
Pomalidomide—Insomnia—Vincristine—muscle cancer	0.000314	0.00262	CcSEcCtD
Pomalidomide—Breast disorder—Methotrexate—muscle cancer	0.000309	0.00258	CcSEcCtD
Pomalidomide—Vertigo—Etoposide—muscle cancer	0.000309	0.00258	CcSEcCtD
Pomalidomide—Leukopenia—Etoposide—muscle cancer	0.000308	0.00257	CcSEcCtD
Pomalidomide—Body temperature increased—Dactinomycin—muscle cancer	0.000307	0.00256	CcSEcCtD
Pomalidomide—Decreased appetite—Vincristine—muscle cancer	0.000301	0.00252	CcSEcCtD
Pomalidomide—Cough—Etoposide—muscle cancer	0.0003	0.00251	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Vincristine—muscle cancer	0.000299	0.0025	CcSEcCtD
Pomalidomide—Fatigue—Vincristine—muscle cancer	0.000299	0.0025	CcSEcCtD
Pomalidomide—Hyponatraemia—Doxorubicin—muscle cancer	0.000298	0.00249	CcSEcCtD
Pomalidomide—Pain—Vincristine—muscle cancer	0.000296	0.00248	CcSEcCtD
Pomalidomide—Constipation—Vincristine—muscle cancer	0.000296	0.00248	CcSEcCtD
Pomalidomide—Pain in extremity—Doxorubicin—muscle cancer	0.000296	0.00248	CcSEcCtD
Pomalidomide—PTGS2—head—muscle cancer	0.000293	0.0132	CbGeAlD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000291	0.00243	CcSEcCtD
Pomalidomide—Hypersensitivity—Dactinomycin—muscle cancer	0.000286	0.00239	CcSEcCtD
Pomalidomide—Confusional state—Etoposide—muscle cancer	0.000283	0.00236	CcSEcCtD
Pomalidomide—Pancytopenia—Methotrexate—muscle cancer	0.000281	0.00235	CcSEcCtD
Pomalidomide—Infection—Etoposide—muscle cancer	0.000279	0.00233	CcSEcCtD
Pomalidomide—Asthenia—Dactinomycin—muscle cancer	0.000278	0.00233	CcSEcCtD
Pomalidomide—Blood creatinine increased—Doxorubicin—muscle cancer	0.000278	0.00232	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—muscle cancer	0.000277	0.00231	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—muscle cancer	0.000276	0.0023	CcSEcCtD
Pomalidomide—Thrombocytopenia—Etoposide—muscle cancer	0.000275	0.0023	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000275	0.0023	CcSEcCtD
Pomalidomide—Body temperature increased—Vincristine—muscle cancer	0.000274	0.00229	CcSEcCtD
Pomalidomide—Skin disorder—Etoposide—muscle cancer	0.000273	0.00228	CcSEcCtD
Pomalidomide—Dry skin—Doxorubicin—muscle cancer	0.000272	0.00227	CcSEcCtD
Pomalidomide—Hyperhidrosis—Etoposide—muscle cancer	0.000272	0.00227	CcSEcCtD
Pomalidomide—ABCB1—renal system—muscle cancer	0.000271	0.0122	CbGeAlD
Pomalidomide—Hypokalaemia—Doxorubicin—muscle cancer	0.00027	0.00225	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—muscle cancer	0.000268	0.00224	CcSEcCtD
Pomalidomide—Diarrhoea—Dactinomycin—muscle cancer	0.000266	0.00222	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—muscle cancer	0.000265	0.00222	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—muscle cancer	0.000265	0.00221	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—muscle cancer	0.000264	0.0022	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—muscle cancer	0.000264	0.0022	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—muscle cancer	0.000261	0.00218	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000261	0.00218	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—muscle cancer	0.000259	0.00217	CcSEcCtD
Pomalidomide—Hypersensitivity—Vincristine—muscle cancer	0.000255	0.00213	CcSEcCtD
Pomalidomide—Dyspnoea—Etoposide—muscle cancer	0.00025	0.00209	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—muscle cancer	0.000249	0.00208	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—muscle cancer	0.000249	0.00208	CcSEcCtD
Pomalidomide—Asthenia—Vincristine—muscle cancer	0.000249	0.00208	CcSEcCtD
Pomalidomide—Vomiting—Dactinomycin—muscle cancer	0.000247	0.00206	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—muscle cancer	0.000246	0.00206	CcSEcCtD
Pomalidomide—Rash—Dactinomycin—muscle cancer	0.000245	0.00204	CcSEcCtD
Pomalidomide—Decreased appetite—Etoposide—muscle cancer	0.000244	0.00204	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—muscle cancer	0.000243	0.00203	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Etoposide—muscle cancer	0.000242	0.00202	CcSEcCtD
Pomalidomide—Fatigue—Etoposide—muscle cancer	0.000242	0.00202	CcSEcCtD
Pomalidomide—Constipation—Etoposide—muscle cancer	0.00024	0.00201	CcSEcCtD
Pomalidomide—Pain—Etoposide—muscle cancer	0.00024	0.00201	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—muscle cancer	0.00024	0.002	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000238	0.00199	CcSEcCtD
Pomalidomide—Diarrhoea—Vincristine—muscle cancer	0.000237	0.00198	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—muscle cancer	0.000234	0.00195	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—muscle cancer	0.000233	0.00195	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—muscle cancer	0.000232	0.00194	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—muscle cancer	0.000232	0.00194	CcSEcCtD
Pomalidomide—Feeling abnormal—Etoposide—muscle cancer	0.000231	0.00193	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—muscle cancer	0.000231	0.00193	CcSEcCtD
Pomalidomide—Nausea—Dactinomycin—muscle cancer	0.00023	0.00192	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—muscle cancer	0.00023	0.00192	CcSEcCtD
Pomalidomide—Dizziness—Vincristine—muscle cancer	0.000229	0.00191	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—muscle cancer	0.000228	0.00191	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—muscle cancer	0.000228	0.00191	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—muscle cancer	0.000225	0.00187	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000224	0.00187	CcSEcCtD
Pomalidomide—Body temperature increased—Etoposide—muscle cancer	0.000222	0.00185	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—muscle cancer	0.000222	0.00185	CcSEcCtD
Pomalidomide—Vomiting—Vincristine—muscle cancer	0.00022	0.00184	CcSEcCtD
Pomalidomide—Cardiac disorder—Methotrexate—muscle cancer	0.00022	0.00184	CcSEcCtD
Pomalidomide—Rash—Vincristine—muscle cancer	0.000219	0.00183	CcSEcCtD
Pomalidomide—Dermatitis—Vincristine—muscle cancer	0.000218	0.00182	CcSEcCtD
Pomalidomide—Headache—Vincristine—muscle cancer	0.000217	0.00181	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000216	0.0018	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—muscle cancer	0.000215	0.0018	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—muscle cancer	0.000215	0.00179	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—muscle cancer	0.000213	0.00178	CcSEcCtD
Pomalidomide—Chills—Methotrexate—muscle cancer	0.000212	0.00177	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—muscle cancer	0.000207	0.00173	CcSEcCtD
Pomalidomide—Hypersensitivity—Etoposide—muscle cancer	0.000207	0.00173	CcSEcCtD
Pomalidomide—Malnutrition—Methotrexate—muscle cancer	0.000206	0.00172	CcSEcCtD
Pomalidomide—Nausea—Vincristine—muscle cancer	0.000206	0.00172	CcSEcCtD
Pomalidomide—ABCB1—bone marrow—muscle cancer	0.000205	0.00923	CbGeAlD
Pomalidomide—Urinary tract disorder—Doxorubicin—muscle cancer	0.000202	0.00169	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—muscle cancer	0.000202	0.00169	CcSEcCtD
Pomalidomide—Asthenia—Etoposide—muscle cancer	0.000202	0.00168	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—muscle cancer	0.000201	0.00168	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—muscle cancer	0.000201	0.00168	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—muscle cancer	0.000199	0.00167	CcSEcCtD
Pomalidomide—Pruritus—Etoposide—muscle cancer	0.000199	0.00166	CcSEcCtD
Pomalidomide—ABCB1—vagina—muscle cancer	0.000196	0.00884	CbGeAlD
Pomalidomide—Diarrhoea—Etoposide—muscle cancer	0.000192	0.0016	CcSEcCtD
Pomalidomide—Anaemia—Methotrexate—muscle cancer	0.000191	0.00159	CcSEcCtD
Pomalidomide—Cardiac disorder—Doxorubicin—muscle cancer	0.00019	0.00159	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—muscle cancer	0.000186	0.00155	CcSEcCtD
Pomalidomide—Dizziness—Etoposide—muscle cancer	0.000186	0.00155	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—muscle cancer	0.000185	0.00155	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—muscle cancer	0.000185	0.00154	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—muscle cancer	0.000185	0.00154	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—muscle cancer	0.000184	0.00154	CcSEcCtD
Pomalidomide—ABCB1—head—muscle cancer	0.000181	0.00817	CbGeAlD
Pomalidomide—Cough—Methotrexate—muscle cancer	0.00018	0.0015	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—muscle cancer	0.00018	0.0015	CcSEcCtD
Pomalidomide—Vomiting—Etoposide—muscle cancer	0.000179	0.00149	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—muscle cancer	0.000178	0.00149	CcSEcCtD
Pomalidomide—Rash—Etoposide—muscle cancer	0.000177	0.00148	CcSEcCtD
Pomalidomide—Dermatitis—Etoposide—muscle cancer	0.000177	0.00148	CcSEcCtD
Pomalidomide—Headache—Etoposide—muscle cancer	0.000176	0.00147	CcSEcCtD
Pomalidomide—Arthralgia—Methotrexate—muscle cancer	0.000175	0.00147	CcSEcCtD
Pomalidomide—ABCB1—testis—muscle cancer	0.000175	0.00789	CbGeAlD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000174	0.00146	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—muscle cancer	0.000173	0.00144	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—muscle cancer	0.000172	0.00143	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—muscle cancer	0.00017	0.00142	CcSEcCtD
Pomalidomide—Infection—Methotrexate—muscle cancer	0.000167	0.0014	CcSEcCtD
Pomalidomide—Nausea—Etoposide—muscle cancer	0.000167	0.00139	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—muscle cancer	0.000165	0.00138	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—muscle cancer	0.000165	0.00138	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—muscle cancer	0.000165	0.00138	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—muscle cancer	0.000163	0.00136	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—muscle cancer	0.000163	0.00136	CcSEcCtD
Pomalidomide—Vertigo—Doxorubicin—muscle cancer	0.00016	0.00134	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—muscle cancer	0.00016	0.00133	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—muscle cancer	0.000156	0.0013	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000153	0.00128	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—muscle cancer	0.000152	0.00127	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—muscle cancer	0.000152	0.00127	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—muscle cancer	0.000151	0.00126	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000151	0.00126	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—muscle cancer	0.00015	0.00125	CcSEcCtD
Pomalidomide—Confusional state—Doxorubicin—muscle cancer	0.000147	0.00123	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—muscle cancer	0.000146	0.00122	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000145	0.00121	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—muscle cancer	0.000145	0.00121	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—muscle cancer	0.000145	0.00121	CcSEcCtD
Pomalidomide—Pain—Methotrexate—muscle cancer	0.000144	0.0012	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—muscle cancer	0.000143	0.00119	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—muscle cancer	0.000143	0.00119	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—muscle cancer	0.000141	0.00118	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—muscle cancer	0.000141	0.00118	CcSEcCtD
Pomalidomide—Feeling abnormal—Methotrexate—muscle cancer	0.000139	0.00116	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—muscle cancer	0.000133	0.00111	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000133	0.00111	CcSEcCtD
Pomalidomide—Insomnia—Doxorubicin—muscle cancer	0.000132	0.0011	CcSEcCtD
Pomalidomide—Dyspnoea—Doxorubicin—muscle cancer	0.00013	0.00108	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—muscle cancer	0.000127	0.00106	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000126	0.00105	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—muscle cancer	0.000126	0.00105	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—muscle cancer	0.000125	0.00104	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—muscle cancer	0.000125	0.00104	CcSEcCtD
Pomalidomide—Hypersensitivity—Methotrexate—muscle cancer	0.000124	0.00104	CcSEcCtD
Pomalidomide—Asthenia—Methotrexate—muscle cancer	0.000121	0.00101	CcSEcCtD
Pomalidomide—Feeling abnormal—Doxorubicin—muscle cancer	0.00012	0.001	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—muscle cancer	0.000119	0.000994	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—muscle cancer	0.000115	0.000962	CcSEcCtD
Pomalidomide—Diarrhoea—Methotrexate—muscle cancer	0.000115	0.000961	CcSEcCtD
Pomalidomide—Dizziness—Methotrexate—muscle cancer	0.000111	0.000929	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—muscle cancer	0.000107	0.000896	CcSEcCtD
Pomalidomide—Vomiting—Methotrexate—muscle cancer	0.000107	0.000893	CcSEcCtD
Pomalidomide—Rash—Methotrexate—muscle cancer	0.000106	0.000886	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—muscle cancer	0.000106	0.000885	CcSEcCtD
Pomalidomide—Headache—Methotrexate—muscle cancer	0.000105	0.00088	CcSEcCtD
Pomalidomide—Asthenia—Doxorubicin—muscle cancer	0.000105	0.000873	CcSEcCtD
Pomalidomide—Pruritus—Doxorubicin—muscle cancer	0.000103	0.000861	CcSEcCtD
Pomalidomide—Nausea—Methotrexate—muscle cancer	9.99e-05	0.000834	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—muscle cancer	9.97e-05	0.000832	CcSEcCtD
Pomalidomide—Dizziness—Doxorubicin—muscle cancer	9.63e-05	0.000804	CcSEcCtD
Pomalidomide—Vomiting—Doxorubicin—muscle cancer	9.26e-05	0.000773	CcSEcCtD
Pomalidomide—Rash—Doxorubicin—muscle cancer	9.18e-05	0.000767	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—muscle cancer	9.18e-05	0.000766	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—muscle cancer	9.13e-05	0.000762	CcSEcCtD
Pomalidomide—Nausea—Doxorubicin—muscle cancer	8.65e-05	0.000723	CcSEcCtD
